These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

500 related articles for article (PubMed ID: 31640815)

  • 21. Mutational landscape of chronic myelomonocytic leukemia and its potential clinical significance.
    Han W; Zhou F; Wang Z; Hua H; Qin W; Jia Z; Cai X; Chen M; Liu J; Chao H; Lu X
    Int J Hematol; 2022 Jan; 115(1):21-32. PubMed ID: 34449040
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Functional features of RUNX1 mutants in acute transformation of chronic myeloid leukemia and their contribution to inducing murine full-blown leukemia.
    Zhao LJ; Wang YY; Li G; Ma LY; Xiong SM; Weng XQ; Zhang WN; Wu B; Chen Z; Chen SJ
    Blood; 2012 Mar; 119(12):2873-82. PubMed ID: 22318203
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Asxl1 C-terminal mutation perturbs neutrophil differentiation in zebrafish.
    Fang X; Xu S; Zhang Y; Xu J; Huang Z; Liu W; Wang S; Yen K; Zhang W
    Leukemia; 2021 Aug; 35(8):2299-2310. PubMed ID: 33483612
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cooperating, congenital neutropenia-associated Csf3r and Runx1 mutations activate pro-inflammatory signaling and inhibit myeloid differentiation of mouse HSPCs.
    Ritter M; Klimiankou M; Klimenkova O; Schambach A; Hoffmann D; Schmidt A; Kanz L; Link DC; Welte K; Skokowa J
    Ann Hematol; 2020 Oct; 99(10):2329-2338. PubMed ID: 32821971
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mutations in ASXL1 are associated with poor prognosis across the spectrum of malignant myeloid diseases.
    Gelsi-Boyer V; Brecqueville M; Devillier R; Murati A; Mozziconacci MJ; Birnbaum D
    J Hematol Oncol; 2012 Mar; 5():12. PubMed ID: 22436456
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical Outcomes and Co-Occurring Mutations in Patients with RUNX1-Mutated Acute Myeloid Leukemia.
    Khan M; Cortes J; Kadia T; Naqvi K; Brandt M; Pierce S; Patel KP; Borthakur G; Ravandi F; Konopleva M; Kornblau S; Kantarjian H; Bhalla K; DiNardo CD
    Int J Mol Sci; 2017 Jul; 18(8):. PubMed ID: 28933735
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Poor Prognostic Implication of ASXL1 Mutations in Korean Patients With Chronic Myelomonocytic Leukemia.
    Kim HY; Lee KO; Park S; Jang JH; Jung CW; Kim SH; Kim HJ
    Ann Lab Med; 2018 Nov; 38(6):495-502. PubMed ID: 30027691
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognostic significance of ASXL1 mutations in myelodysplastic syndromes and chronic myelomonocytic leukemia: A meta-analysis.
    Lin Y; Zheng Y; Wang ZC; Wang SY
    Hematology; 2016 Sep; 21(8):454-61. PubMed ID: 27077763
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Overexpression or knock-down of runt-related transcription factor 1 affects BCR-ABL-induced proliferation and migration in vitro and leukemogenesis in vivo in mice.
    Yang LJ; Yu WD; DU JB; Chao S; Chen MX; Zhao HH; Guo JZ
    Chin Med J (Engl); 2009 Feb; 122(3):331-7. PubMed ID: 19236814
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Myelodysplastic syndromes are induced by histone methylation–altering ASXL1 mutations.
    Inoue D; Kitaura J; Togami K; Nishimura K; Enomoto Y; Uchida T; Kagiyama Y; Kawabata KC; Nakahara F; Izawa K; Oki T; Maehara A; Isobe M; Tsuchiya A; Harada Y; Harada H; Ochiya T; Aburatani H; Kimura H; Thol F; Heuser M; Levine RL; Abdel-Wahab O; Kitamura T
    J Clin Invest; 2013 Nov; 123(11):4627-40. PubMed ID: 24216483
    [TBL] [Abstract][Full Text] [Related]  

  • 31. ASXL1 mutations are frequent and prognostically detrimental in CSF3R-mutated chronic neutrophilic leukemia.
    Elliott MA; Pardanani A; Hanson CA; Lasho TL; Finke CM; Belachew AA; Tefferi A
    Am J Hematol; 2015 Jul; 90(7):653-6. PubMed ID: 25850813
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Myelodysplastic syndromes without peripheral monocytosis but with evidence of marrow monocytosis share clinical and molecular characteristics with CMML.
    Schuler E; Frank F; Hildebrandt B; Betz B; Strupp C; Rudelius M; Aul C; Schroeder T; Gattermann N; Haas R; Germing U
    Leuk Res; 2018 Feb; 65():1-4. PubMed ID: 29216536
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The role of ASXL1 in hematopoiesis and myeloid malignancies.
    Asada S; Fujino T; Goyama S; Kitamura T
    Cell Mol Life Sci; 2019 Jul; 76(13):2511-2523. PubMed ID: 30927018
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Genetic typing of CBL, ASXL1, RUNX1, TET2 and JAK2 in juvenile myelomonocytic leukaemia reveals a genetic profile distinct from chronic myelomonocytic leukaemia.
    Pérez B; Kosmider O; Cassinat B; Renneville A; Lachenaud J; Kaltenbach S; Bertrand Y; Baruchel A; Chomienne C; Fontenay M; Preudhomme C; Cavé H
    Br J Haematol; 2010 Dec; 151(5):460-8. PubMed ID: 20955399
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Molecular and clinical analyses of PHF6 mutant myeloid neoplasia provide their pathogenesis and therapeutic targeting.
    Kubota Y; Gu X; Terkawi L; Bodo J; Przychodzen BP; Awada H; Williams N; Gurnari C; Kawashima N; Aly M; Durmaz A; Mori M; Ponvilawan B; Kewan T; Bahaj W; Meggendorfer M; Jha BK; Visconte V; Rogers HJ; Haferlach T; Maciejewski JP
    Nat Commun; 2024 Feb; 15(1):1832. PubMed ID: 38418452
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Aberrant histone modifications induced by mutant ASXL1 in myeloid neoplasms.
    Asada S; Kitamura T
    Int J Hematol; 2019 Aug; 110(2):179-186. PubMed ID: 30515738
    [TBL] [Abstract][Full Text] [Related]  

  • 37. ASXL2 is essential for haematopoiesis and acts as a haploinsufficient tumour suppressor in leukemia.
    Micol JB; Pastore A; Inoue D; Duployez N; Kim E; Lee SC; Durham BH; Chung YR; Cho H; Zhang XJ; Yoshimi A; Krivtsov A; Koche R; Solary E; Sinha A; Preudhomme C; Abdel-Wahab O
    Nat Commun; 2017 May; 8():15429. PubMed ID: 28516957
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Clinical, Molecular, and Mechanistic Basis of RUNX1 Mutations Identified in Hematological Malignancies.
    Yokota A; Huo L; Lan F; Wu J; Huang G
    Mol Cells; 2020 Feb; 43(2):145-152. PubMed ID: 31964134
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of mutational profiles and clinical outcomes in patients with acute myeloid leukemia with mutated
    Nguyen L; Zhang X; Roberts E; Yun S; McGraw K; Abraham I; Song J; Braswell D; Qin D; Sallman DA; Lancet JE; List AF; Moscinski LC; Padron E; Zhang L
    Leuk Lymphoma; 2020 Jun; 61(6):1395-1405. PubMed ID: 32091281
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Genome profiling of chronic myelomonocytic leukemia: frequent alterations of RAS and RUNX1 genes.
    Gelsi-Boyer V; Trouplin V; Adélaïde J; Aceto N; Remy V; Pinson S; Houdayer C; Arnoulet C; Sainty D; Bentires-Alj M; Olschwang S; Vey N; Mozziconacci MJ; Birnbaum D; Chaffanet M
    BMC Cancer; 2008 Oct; 8():299. PubMed ID: 18925961
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.